Endo, Shunji http://orcid.org/0000-0003-0720-4156
Terazawa, Tetsuji
Goto, Masahiro
Tanaka, Ryo
Kato, Takeshi
Fujitani, Kazumasa
Kawakami, Hisato
Sakai, Daisuke
Kurokawa, Yukinori
Tsujinaka, Toshimasa
Shimokawa, Toshio
Satoh, Taroh
Funding for this research was provided by:
Yakult Honsha
Article History
Received: 26 November 2021
Accepted: 13 July 2022
First Online: 23 July 2022
Declarations
:
: The Osaka Gastrointestinal Cancer Chemotherapy Study Group Protocol Review Committee approved this study protocol on March 25, 2019, and Osaka Prefectural Hospital Organization Osaka International Cancer Institute Certified Review Board approved it on September 12, 2019 (CRB5180012). Japan Registry of Clinical Trials registered it on October 11, 2019 (jRCTs051190060). The first patient was recruited on October 15, 2019. This study is being conducted according to the principles of the Declaration of Helsinki. All patients are required to provide written informed consent.
: Not applicable.
: TTe reports honoraria for speaker activities from Chugai Pharmaceutical Co. Ltd., Eli Lilly Co. Ltd., Taiho Pharmaceutical Co. Ltd., Sanofi Co. Ltd. and salary from Shionogi Co. Ltd. MG reports grants, personal fees and non-financial support from Taiho Pharmaceutical Co. Ltd.. KK reports honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, Yakult Honsha Co., Ltd., and Taiho Pharmaceutical Co., Ltd.; and research funding from Chugai Pharmaceutical Co., Ltd.. HK reports consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd.; honoraria from Bristol-Myers Squibb Co. Ltd., AstraZeneca K.K., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Honsha Co., Ltd., and Taiho Pharmaceutical Co. Ltd.; lecture fees from Glaxo Smith Kline K.K., Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co., Ltd.; and research funding from Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Kobayashi Pharmaceutical. Co., Ltd., and Eisai Co. Ltd.. DS reports grants from Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Ono pharmaceutical Co., Ltd., and Eli Lilly and Company; and speakers bureaus from Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd.. YK reports grants from Taiho Pharmaceutical, Ono Pharmaceutical, and Yakult Honsha; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Taiho Pharmaceutical, Ono Pharmaceutical, Eli Lilly, Yakult Honsha, Bristol-Myers Squibb, Daiichi Sankyo, Nippon Kayaku, and Takeda Pharmaceutical. TSa reports grants, personal fees and other from Ono Pharmaceutical, grants, personal fees and other from Chugai Pharmaceutical, grants, personal fees and other from Yakult Honsha, grants and personal fees from Elli Lilly, grants and personal fees from MSD, grants from Giliad Sciences, grants from Palexell, grants and personal fees from Bristol Myers Squib, grants and personal fees from Astellas, grants from Daiichi Sankyo, grants and personal fees from Taiho Pharmaceutical, personal fees from Takara Bio, personal fees from Sanofi-Aventis, outside the submitted work. The other authors declare that they have no competing interests.